“TECNALIA collaborates with pharmaceutical laboratories to transform scientific challenges into technological solutions”
Pharmaceutical innovation for therapeutic effectiveness
Advanced formulations are becoming a game changer in the pharmaceutical industry. This technology redefines the way active substances are administered, and also makes it easier for them to be used by patients. It helps to establish highly convenient pharmaceutical combinations in clinical use, makes treatment more accessible in certain patient groups, reduces treatment drop-out, and helps to increase patient safety and product sustainability.
- From a technical point of view, an advanced formulation is a new galenic approach that helps to significantly improve critical aspects of the drug such as drug delivery, modulating release, absorption and bioavailability of the active ingredient, providing technology that allows the combination of several different drugs in the same treatment, using technology that could range from nanoparticles to controlled release systems, liposomes, microemulsions, and bioadhesive matrices, bi-nucleus or bi-layer tablets, and more.
- These platforms overcome pharmaceutical barriers that are limited in conventional technology and improve critical aspects of the drugs, offering new benefits in clinical use and quality of life for patients.
Beyond pharmacokinetics: personalisation and adherence
One of the main benefits of these formulations is their ability to personalise treatments according to the patients’ pharmacogenetic profiles. In addition, technology such as multilayer tablets, transdermal patches and sustained-release systems significantly improve adherence.
Use cases and industrial scale-up
At TECNALIA, the development of advanced formulations has a comprehensive approach: from physicochemical characterisation of the active ingredient to the galenic and analytical design and industrial scale-up under GMP regulations.
The use of tools such as in silico modelling and pharmaceutical 3D printing, amongst others, accelerates development cycles and reduces regulatory risk.
A smarter, more sustainable future
The convergence between materials science, biotechnology and pharmacology is leading to a new stage in drug development which is capable of responding to physiological stimuli (smart formulations) or of releasing the drug in specific tissues through molecular targeting systems. These innovations not only increase clinical outcomes, but also optimise responsible use of drugs, their impact on society and the environment.
- TECNALIA’s pharmaceutical development laboratory and manufacturing plant collaborates with pharmaceutical laboratories to transform scientific challenges into high value-added technological solutions.
- As a CDMO (Contract Development and Manufacturing Organisation), TECNALIA offers comprehensive development and manufacturing services for the pharmaceutical industry. Its pharmaceutical development and manufacturing infrastructure are equipped to support customers at every stage of the process, from idea to market.
